Microplastics detected in cat placentas and fetuses during early pregnancy
Peer-Reviewed Publication
Updates every hour. Last Updated: 2-May-2025 10:57 ET (2-May-2025 14:57 GMT/UTC)
The Icahn School of Medicine at Mount Sinai has launched the AI Small Molecule Drug Discovery Center, a bold endeavor that harnesses artificial intelligence (AI) to revolutionize drug development. The new Center will integrate AI with traditional drug discovery methods to identify and design new small-molecule therapeutics with unprecedented speed and precision. Unlike conventional drug discovery, which can take years and cost billions, AI-driven approaches enable researchers to rapidly navigate a vast chemical landscape, including natural products, to pinpoint promising drug candidates. By leveraging Mount Sinai’s world-leading expertise in machine learning, chemical biology, and biomedical data science, the Center aims to bring innovative treatments to patients faster—particularly for diseases with urgent unmet needs, including cancer, metabolic disorders, and neurodegenerative diseases.
A wife and husband professor team at Michigan State University are collaborating with researchers at the University of California, Riverside to create a new light-activated “smart” bomb to treat aggressive breast cancer.
Sophia Lunt, an MSU professor in biochemistry and molecular biology in the College of Natural Science, and Richard Lunt, an MSU professor and Johansen-Crosby Endowed Professor in Chemical Engineering in the College of Engineering, along with Vincent Lavallo, a professor of chemistry at the University of California, Riverside, have combined their expertise to help develop new light-sensitive chemicals called cyanine-carborane salts that are used in photodynamic therapy, or PDT, to destroy metastatic breast cancer tumors in mice with minimal side effects.
Researchers from the universities in Konstanz and Vienna discover a new class of antibiotic that selectively targets Neisseria gonorrhoeae, the bacterium that causes gonorrhoea. These substances trigger a self-destruction program, which also operates in multi-resistant variants of the pathogen. The novel findings are published in the current issue of Nature Microbiology.